cytochrome P450 family 3 subfamily A member 4Genealiases: CP33 · CP34 · CYP3A · CYP3A3 · CYPIIIA3 · CYPIIIA4
Q-omics provides the consensus-scored CYP3A4 profile across patient tissues and cancer cell-line models. CYP3A4 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CYP3A4 is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, CYP3A4 RNA expression shows 16,642 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, HNSC, and UVM as cancer lineages where CYP3A4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CYP3A4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CYP3A4 survival associations across molecular data types. CYP3A4 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (7) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CYP3A4 RNA expression–survival associations across cancer types. High CYP3A4 expression shows unfavorable associations in CHOL, but favorable associations in KIRC, ACC, SCLC, MESO and LAML. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CYP3A4 RNA expression.
This table summarizes CYP3A4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for CYP3A4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CYP3A4 shows lower tumor expression in HNSC, COAD, KIRP, LIHC, KIRC and BRCA. The HNSC box plot shows higher CYP3A4 RNA expression in normal versus tumor tissue (log2 FC = −0.696, t-test p < 0.001).
This table shows molecular features associated with CYP3A4 in patient tissues and cancer cell lines. In patient samples, CYP3A4 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CYP3A4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Leukemia.
